Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

April 23, 2018April 23, 2018

Investigational QBECO SSI Therapy Enters Phase 2 Clinical Trial for Crohn’s

News

Qu Biologics soon will begin recruiting participants for a Phase 2 clinical trial to continue investigating the company’s special platform of immunotherapies, collectively called Site Specific Immunomodulators (SSIs), as a potential ... Read more

April 18, 2018April 18, 2018

Exposure to Livestock Farms Alone Doesn’t Increase Risk of IBD, Dutch Study Suggests

News

Researchers in the Netherlands found that exposure to livestock farms alone carries little risk for developing inflammatory bowel disease (IBD). Their findings suggest that residents in livestock-dense areas may be ... Read more

April 11, 2018April 11, 2018

Oral PL-8177 Reduces Gut Inflammation in Rat Model of IBD, New Results Show

News

Palatin Technologies‘, investigational PL-8177, taken orally, reached the large intestine and colon, resulting in significantly reduced inflammation and damage in a bowel inflammation rat model. The poster on the study, ... Read more

March 12, 2018March 12, 2018

FDA Advisory Panel Favors Extended Use of Xeljanz by Certain Ulcerative Colitis Patients

News

An advisory arm of the U.S. Food and Drug Administration (FDA) gave two positive recommendations to Pfizer’s supplemental New Drug Application, seeking FDA approval for extended use of Xeljanz (tofacitinib) by certain adult ... Read more

March 5, 2018

Entyvio Outperforms Anti-TNF Alpha Therapies in Real-world Bowel Disease Studies

News

Real-world treatment results showed that Takeda’s Entyvio (vedolizumab) was better than an anti-tumor necrosis factor-alpha therapy at alleviating moderate to severe ulcerative colitis or Crohn’s disease, according to several studies. They ... Read more

January 31, 2018January 31, 2018

More Severe IBD Boosts Risk for Non-alcoholic Fatty Liver Disease, Italian Study Suggests

News

The risk that inflammatory bowel disease (IBD) patients will develop non-alcoholic fatty liver disease (NAFLD) increases as IBD worsens, according to Italian researchers. Their study “Non-alcoholic fatty liver disease phenotypes ... Read more

January 26, 2018January 26, 2018

Researchers Target Specific Gut Bacteria to Control Inflammation in Mice Study of Colitis

News

Researchers at UT Southwestern Medical Center have discovered a way to target a specific population of bacteria that promotes gut inflammation in mice. While more studies are needed, they believe ... Read more

January 11, 2018

Vitality Biopharma Unveils Cannabis-based Potential Bowel Disease Therapy

News

Vitality Biopharma has developed a cannabis-based potential treatment for inflammatory bowel diseases. Its annoucement about VITA-100 comes as U.S. regulators have been approving cannabis-based products for various disorders. VITA-100 delivers two of the active ... Read more

January 2, 2018

Defective MDR1 Gene May Promote Ileal Crohn’s Disease, Study Suggests

News

Researchers have found that the MDR1 gene helps protect immune cells from the damaging effects of bile acids in the intestine, preventing a condition known as ileal Crohn’s disease. The findings ... Read more

December 18, 2017December 18, 2017

Variation in Single Gene May Determine Response to Humira in IBD Patients, Study Reports

News

A single variation in the DNA sequence of a particular gene, called ATG16L1, was associated with response to Humira (adalimumab) treatment in a group of people with inflammatory bowel disease ... Read more